MYM Nutraceuticals Inc. (CSE:MYM) (FRANKFURT:0MY) (OTCMKTS:MYMMF) (“MYM” or the “Company” is pleased to announce that it has established an at-the-market equity distribution program (“ATM Program”) that allows the Company to issue common shares from treasury (“Common Shares”), through GMP Securities L.P., as agent (the “Agent”), to the public from time to time at the Company’s discretion, at the prevailing market price when sold through the Canadian Securities Exchange (“CSE”) or on any other existing trading market for the Common Shares in Canada.

Sales of Common Shares under the ATM Program will be made pursuant to the terms of an equity distribution agreement dated October 17, 2018 (“Equity Distribution Agreement”) between the Company and the Agent.


Sales of Common Shares will be made through “at-the-market distributions”, as defined in National Instrument 44-102 – Shelf Distributions, on the CSE or on any other existing trading market for the Common Shares in Canada. The Common Shares will be distributed at the prevailing market prices at the time of the sale and, as a result, prices may vary among purchasers and during the period of distribution.

Sale of Common Shares under the ATM Program are being made pursuant to a prospectus supplement dated October 17, 2018 (the “Prospectus Supplement”) to the Company’s short form base shelf prospectus dated October 9, 2018 (the “Base Shelf Prospectus”). Copies of the Prospectus Supplement, the Base Shelf Prospectus and the Equity Distribution Agreement may be obtained on request without charge from the Corporate Secretary of MYM Nutraceuticals Inc. at Suite 250, 1095 West Pender Street, Vancouver, British Columbia, V6E 2M6, Telephone (604) 899-5267, and are also available electronically on SEDAR at www.sedar.com.

The Company intends to use the net proceeds from the ATM Program, if any, to fund ongoing operations, capital expenditures and potential future acquisitions or investments. For further information on the use of net proceeds from the ATM Program, see the “Use of Proceeds” section in the Prospectus Supplement.

This news release shall not in any circumstances constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to the registration or qualification under the applicable securities laws of any jurisdiction.

About MYM Nutraceuticals Inc.

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products. MYM is a shareholder in two production projects in Quebec that when completed will have over 1.5 million sf of production space. MYM is also a shareholder in a 1.2 million sf production project (Northern Rivers Project) in New South Wales, Australia. Australia is an exciting new market that has recently legalized medicinal cannabis. To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE:MYM) (OTC:MYMMF) (FRA:0MY) (DEU:0MY) (MUN:0MY) (STU:0MY).

On behalf of the Board of Directors

“Erick Factor”

Executive Chairman

Investor Relations

investors@mym.ca mailto:

FORWARD-LOOKING STATEMENTS

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE), nor its Regulatory Services provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

Certain statements (“forward-looking statements”) in this news release may contain forward-looking information concerning the anticipated sale and distribution of Common Shares under the ATM Program, the volume and timing of the sale and distribution of Common Shares under the ATM Program, the Company’s intended use of the net proceeds from the ATM Program, plans related to the Company’s business, the anticipated production capacity of the Company’s projects and other matters that may occur in the future, made as of the date of this news release. Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors which could cause actual events or results to differ from those expressed or implied by the forward-looking statements. Such factors include, among others, risks related to MYM’s ability to raise capital under the ATM Program or additional capital, the Company’s use of proceeds, the Company’s ability to fulfill its obligations under the Equity Distribution Agreement and the Company’s ability to complete its production projects as anticipated. Forward-looking statements are based on certain assumptions that management believes are reasonable at the time they are made. In making the forward-looking statements included in this news release, the Company has applied several material assumptions, including, but not limited to, that the Company will be able to raise capital under the ATM Program or any additional capital and the use of the proceeds will proceed as planned, the Company and other parties will be able to complete and satisfy obligations under the Equity Distribution Agreement and the Company will be able to complete its production projects as anticipated. There can be no assurance that forward-looking statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as otherwise required by applicable securities legislation.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities law and may not be offered or sold in the “United States”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Click here to connect with MYM Nutraceuticals Inc. (CSE:MYM) for an Investor Presentation.

Source: www.thenewswire.com

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www.rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less

Trading resumes in:

Company: 4Front Ventures Corp.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES /

  4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) is pleased to announce that it has completed its previously announced bought deal prospectus offering (the ” Offering “) of units of the Company (” Units “), for aggregate gross proceeds of C$17,251,150 including full exercise of the over-allotment option granted to the underwriters in connection therewith.

Keep reading... Show less

Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff

Tactile Systems Technology (NASDAQ:TCMD)
Class Period:
May 7, 2018 – June 8, 2020
Deadline: November 30, 2020
For more info: www.bgandg.com/tcmd

Keep reading... Show less

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less